Prostate Cancer Therapy with Annexin II Nanoparticles

膜联蛋白 II 纳米颗粒治疗前列腺癌

基本信息

项目摘要

DESCRIPTION (provided by applicant): Annexin II expression is lost during progression of prostate cancer from the prostate intraepithelial neoplasia (PIN) stage to cancer. Annexin II functions both at the cell surface and in the nucleus: At the cell surface, Annexin II organizes a proteolytic center proposed to regulate angiogenesis, tumor invasion and metastasis. Annexin II in the cell nucleus regulates cell proliferation and DNA synthesis. The long-term goal of our research program is to identify the key molecular events that lead to development and progression of prostate cancer, in order that improved detection methods and therapies to treat this disease can be developed. The objective of studies outlined in this application is to determine if replacement of the Annexin II gene results in inhibition of prostate cancer growth and angiogenesis. Our central hypothesis is that the nanoparticle-mediated sustained expression of Annexin II gene would lead to prolonged accumulation of Annexin II in the nucleus resulting in inhibition of cell proliferation and sustained cell surface Annexin II expression resulting anti-angiogenesis, collectively inhibiting prostate cancer growth. We propose the following specific aims: Aim 1: To determine the in vitro effect of nanoparticle-mediated Annexin II delivery on phenotypes associated with prostate cancer growth. The working hypothesis for this aim, based upon preliminary data, is that sustained nanoparticle- mediated nuclear accumulation of Annexin II results in inhibition of prostate cancer cell proliferation. Aim 2: To determine the effect of nanoparticle-mediated Annexin II delivery on growth and angiogenesis of prostate tumors in a mouse model system. The working hypothesis for this aim is that sustained delivery of the anti-angiogenic Annexin II to prostate tumors in mice leads to reduction in tumor number and volume, and prolongs animal survival. These studies are innovative in that we are proposing a new approach of Annexin ll-based therapy for prostate cancer. At the completion of this project, it is our expectation that we will have determined that the nanoparticle-mediated sustained Annexin II gene delivery would result in retardation of prostate growth and reduced tumor burden.
描述(由申请人提供):在

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Efficient nanoparticle mediated sustained RNA interference in human primary endothelial cells.
  • DOI:
    10.1088/0957-4484/22/44/445101
  • 发表时间:
    2011-11-04
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    Mukerjee A;Shankardas J;Ranjan AP;Vishwanatha JK
  • 通讯作者:
    Vishwanatha JK
Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy.
  • DOI:
  • 发表时间:
    2009-10
  • 期刊:
  • 影响因子:
    2
  • 作者:
    A. Mukerjee;J. Vishwanatha
  • 通讯作者:
    A. Mukerjee;J. Vishwanatha
Bioinspired Nanoparticles Engineered for Enhanced Delivery to the Bone.
  • DOI:
    10.1021/acsanm.9b01226
  • 发表时间:
    2019-10-25
  • 期刊:
  • 影响因子:
    5.9
  • 作者:
    Gdowski AS;Lampe JB;Lin VJT;Joshi R;Wang YC;Mukerjee A;Vishwanatha JK;Ranjan AP
  • 通讯作者:
    Ranjan AP
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMBOOR K. VISHWANATHA其他文献

JAMBOOR K. VISHWANATHA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMBOOR K. VISHWANATHA', 18)}}的其他基金

NRMNet: A national resource for mentorship and networking to enhance diversity
NRMNet:用于增强多样性的指导和网络的国家资源
  • 批准号:
    10452553
  • 财政年份:
    2019
  • 资助金额:
    $ 11.93万
  • 项目类别:
NRMNet: A national resource for mentorship and networking to enhance diversity
NRMNet:用于增强多样性的指导和网络的国家资源
  • 批准号:
    10201660
  • 财政年份:
    2019
  • 资助金额:
    $ 11.93万
  • 项目类别:
NRMNet: A national resource for mentorship and networking to enhance diversity
NRMNet:用于增强多样性的指导和网络的国家资源
  • 批准号:
    10655589
  • 财政年份:
    2019
  • 资助金额:
    $ 11.93万
  • 项目类别:
2/2 Langston University-UNTHSC Partnership for Cancer Research and Education
2/2 兰斯顿大学-UNTHSC 癌症研究和教育合作伙伴关系
  • 批准号:
    10237230
  • 财政年份:
    2018
  • 资助金额:
    $ 11.93万
  • 项目类别:
2/2 Langston University-UNTHSC Partnership for Cancer Research and Education
2/2 兰斯顿大学-UNTHSC 癌症研究和教育合作伙伴关系
  • 批准号:
    9789220
  • 财政年份:
    2018
  • 资助金额:
    $ 11.93万
  • 项目类别:
2/2 Langston University-UNTHSC Partnership for Cancer Research and Education
2/2 兰斯顿大学-UNTHSC 癌症研究和教育合作伙伴关系
  • 批准号:
    10005233
  • 财政年份:
    2018
  • 资助金额:
    $ 11.93万
  • 项目类别:
Investigating serum exosomal annexin A2 in promoting aggressive TNBC in African American women
研究血清外泌体膜联蛋白 A2 在促进非洲裔美国女性侵袭性 TNBC 中的作用
  • 批准号:
    10425353
  • 财政年份:
    2017
  • 资助金额:
    $ 11.93万
  • 项目类别:
Investigating serum exosomal annexin A2 in promoting aggressive TNBC in African American women
研究血清外泌体膜联蛋白 A2 在促进非洲裔美国女性侵袭性 TNBC 中的作用
  • 批准号:
    9388064
  • 财政年份:
    2017
  • 资助金额:
    $ 11.93万
  • 项目类别:
Texas Minority Health, Research and Outreach (MiHERO)
德克萨斯州少数族裔健康、研究和外展 (MiHERO)
  • 批准号:
    10764371
  • 财政年份:
    2017
  • 资助金额:
    $ 11.93万
  • 项目类别:
Investigating serum exosomal annexin A2 in promoting aggressive TNBC in African American women
研究血清外泌体膜联蛋白 A2 在促进非洲裔美国女性侵袭性 TNBC 中的作用
  • 批准号:
    10001985
  • 财政年份:
    2017
  • 资助金额:
    $ 11.93万
  • 项目类别:

相似国自然基金

D型IC-8多肽修饰的还原敏感型RHB自组装双靶向核酸递送载体的研究
  • 批准号:
    81273459
  • 批准年份:
    2012
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目

相似海外基金

AIDS Malignancy Clinical Trials Consortium
艾滋病恶性肿瘤临床试验联盟
  • 批准号:
    7689546
  • 财政年份:
    2006
  • 资助金额:
    $ 11.93万
  • 项目类别:
AIDS Malignancy Clinical Trials Consortium
艾滋病恶性肿瘤临床试验联盟
  • 批准号:
    7689549
  • 财政年份:
    2006
  • 资助金额:
    $ 11.93万
  • 项目类别:
AIDS Malignancy Clinical Trials Consortium
艾滋病恶性肿瘤临床试验联盟
  • 批准号:
    7689545
  • 财政年份:
    2006
  • 资助金额:
    $ 11.93万
  • 项目类别:
Prostate Cancer Therapy with Annexin II Nanoparticles
膜联蛋白 II 纳米颗粒治疗前列腺癌
  • 批准号:
    6925691
  • 财政年份:
    2005
  • 资助金额:
    $ 11.93万
  • 项目类别:
Role and Utility of Annexins in Endothelium of Solid Tum
膜联蛋白在实体肿瘤内皮细胞中的作用和用途
  • 批准号:
    7265209
  • 财政年份:
    2004
  • 资助金额:
    $ 11.93万
  • 项目类别:
Role and Utility of Annexins in Endothelium of Solid Tum
膜联蛋白在实体肿瘤内皮细胞中的作用和用途
  • 批准号:
    7462260
  • 财政年份:
    2004
  • 资助金额:
    $ 11.93万
  • 项目类别:
Ventricular Remodeling in the Adapted Heart
适应心脏的心室重塑
  • 批准号:
    8231289
  • 财政年份:
    2003
  • 资助金额:
    $ 11.93万
  • 项目类别:
Ventricular Remodeling in the Adapted Heart
适应心脏的心室重塑
  • 批准号:
    7788214
  • 财政年份:
    2003
  • 资助金额:
    $ 11.93万
  • 项目类别:
Ventricular Remodeling in the Adapted Heart
适应心脏的心室重塑
  • 批准号:
    8027761
  • 财政年份:
    2003
  • 资助金额:
    $ 11.93万
  • 项目类别:
Ventricular Remodeling in the Adapted Heart
适应心脏的心室重塑
  • 批准号:
    7666637
  • 财政年份:
    2003
  • 资助金额:
    $ 11.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了